基于18F-EF5 PET的可成像乏氧预测接受高适形放疗肿瘤的局部复发
研究前瞻性纳入28例接受放疗的局限性肺或其他肿瘤患者,治疗前行18F-EF5 PET显像,并部分进行氧合功能干预后重复显像。基线可成像乏氧见于43%(12/28)患者,乏氧肿瘤12个月局部复发率为30%,无乏氧肿瘤为0%(P<.01)。
要点
- 基线18F-EF5 PET可成像乏氧见于43%(12/28)患者。
- 乏氧肿瘤12个月局部复发率30%,无乏氧肿瘤为0%(P<.01)。
- 碳氧混合气吸入与可成像乏氧减少显著相关,二氯乙酸在本方案条件下无显著变化。
核心结论
- 18F-EF5 PET无创乏氧显像在本研究人群中约40%的肿瘤中识别出可成像乏氧。
- 接受高适形放疗后,可成像乏氧肿瘤的局部复发率高于无乏氧肿瘤。
研究设计与样本
- 前瞻性研究纳入28例接受放疗的局限性肺或其他肿瘤患者,治疗前接受18F-EF5 PET显像。
- 根据18F-EF5肿瘤摄取水平,患者接受碳氧混合气吸入或口服二氯乙酸进行肿瘤氧合功能干预,随后重复18F-EF5 PET。
- 采用Cox模型评估可成像乏氧与治疗后临床结局的相关性。
主要发现
- 基线可成像乏氧见于43%(12/28)患者,包括16例接受立体定向消融放疗的早期非小细胞肺癌患者中的6例和12例其他癌症患者中的6例。
- 碳氧混合气吸入与可成像乏氧减少显著相关,二氯乙酸在本方案条件下未导致显著变化。
- 可成像乏氧肿瘤12个月局部复发率为30%,无乏氧肿瘤为0%(P<.01)。
关键数值与推荐
- 肿瘤乏氧亚体积定义为18F-EF5摄取高于血池18F-EF5摄取第95百分位的肿瘤体素比例。
- 基线18F-EF5 PET显示乏氧亚体积≥10%的肿瘤归类为影像学乏氧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tumor hypoxia contributes to radiation resistance. A noninvasive assessment of tumor hypoxia would be valuable for prognostication and possibly selection for hypoxia-targeted therapies. 18F-pentafluorinated etanidazole (18F-EF5) is a nitroimidazole derivative that has demonstrated promise as a positron emission tomography (PET) hypoxia imaging agent in preclinical and clinical studies. However, correlation of imageable hypoxia by 18F-EF5 PET with clinical outcomes after radiation therapy remains limited. METHODS AND MATERIALS: Our study prospectively enrolled 28 patients undergoing radiation therapy for localized lung or other tumors to receive pretreatment 18F-EF5 PET imaging. Depending on the level of 18F-EF5 tumor uptake, patients underwent functional manipulation of tumor oxygenation with either carbogen breathing or oral dichloroacetate followed by repeated 18F-EF5 PET. The hypoxic subvolume of tumor was defined as the proportion of tumor voxels exhibiting higher 18F-EF5 uptake than the 95th percentile of 18F-EF5 uptake in the blood pool. Tumors with a hypoxic subvolume ≥ 10% on baseline 18F-EF5 PET imaging were classified as hypoxic by imaging. A Cox model was used to assess the correlation between imageable hypoxia and clinical outcomes after treatment. RESULTS: At baseline, imageable hypoxia was demonstrated in 43% of all patients (12 of 28), including 6 of 16 patients with early-stage non-small cell lung cancer treated with stereotactic ablative radiation therapy and 6 of 12 patients with other cancers. Carbogen breathing was significantly associated with decreased imageable hypoxia, while dichloroacetate did not result in a significant change under our protocol conditions. Tumors with imageable hypoxia had a higher incidence of local recurrence at 12 months (30%) than those without (0%) (P < .01). CONCLUSIONS: Noninvasive hypoxia imaging by 18F-EF5 PET identified imageable hypoxia in about 40% of tumors in our study population. Local tumor recurrence after highly conformal radiation therapy was higher in tumors with imageable hypoxia.
引用
- Qian Y, Von Eyben R, Liu Y, et al. 18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 29859786. doi:10.1016/j.ijrobp.2018.03.045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。